Loading…
← CockpitCompetitor Analysis › FENC Fennec Pharmaceuticals Inc.Open in the cockpit ↗

Fennec Pharmaceuticals Inc.FENCCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology
Momentum leader 94
Mkt cap
$471M
US dollars, full cap
Free float
86%
of shares outstanding
$/day
$3.21M
20-day average traded
Fwd P/E
16.9×
forward earnings
ROIC−WACC
n/a
WACC 11.5%
Hurdle
-146 pp
Req g minus delivered
Next earnings
132 days
30 Mar 2027
Close · USD$13.33
1D-1.8%
1W+25.3%
1M+27.4%
3M+17.4%
6M+36.7%
YTD+73.1%
1Y+52.3%
ATR %6.0%
Beta1.39
52w lowhigh3.8% off high

What Fennec Pharmaceuticals does

Employees: 35

Fennec Pharmaceuticals at a glance

Size Fennec Pharmaceuticals (FENC) is a United States Health Care company (Biotechnology) with a market value of $471M, the 2715th largest of 3,085 United States companies the cockpit tracks. Shares closed at $13.33 on 18 Nov 2026.

Performance Over six months the shares gained 36.7%, against -15.8% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd highest of 19 in its peer set.

Growth Revenue grew 71.1% over the last twelve months (peer median -4.3%); the operating margin is 4.9% (peer median -17.2%).

Valuation It trades at 16.9× forward earnings against a peer median of 21.5× (2nd cheapest of 6).

Price implies For today's price to make sense, revenue must grow about 59% a year for seven years (Req g). Recent delivered growth is +205%, so the hurdle is -146 pp: the price already allows for a slowdown.

Next results Next results expected around 30 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010012014021 May 202621 Aug 202618 Nov 2026FENC 134Peer median 83
Six months, rebased to 100: Fennec Pharmaceuticals against the median of its 20 peers (local-currency closes).

Fennec Pharmaceuticals financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$66.4M$44.6M$47.5M$21.3M$1.53M
Revenue growth—-6%+124%+1,284%—
Gross profit$62.5M$40.9M$44.4M$20.0M$1.45M
EBITDA$3.33M-$6.28M$2.57M-$12.8M-$22.6M
Net income$1.67M-$9.74M-$436,000-$16.0M-$23.7M
Free cash flow$1.18M-$14.4M$27.0M-$17.1M-$18.1M
Capital expenditure$0$0$0$0$0
Total debt$0$0$18.1M$29.7M$24.6M

Quarterly statements and history in the cockpit →

Fennec Pharmaceuticals competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%+20%KMDADMACNGNEMNPR4147CBIOSTTK0419606586603255115180ARVN300858IRLAFENC6-month return →1-month return →
Up and to the right = strong over both horizons. Fennec Pharmaceuticals is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%+60%20×30×KMDA603255300858603739FENCRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Fennec Pharmaceuticals is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%+150%+200%0%100%200%KMDA688247603739FENCGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Fennec Pharmaceuticals is the large dot.

Fennec Pharmaceuticals competitors and peer comparison

How Fennec Pharmaceuticals compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Fennec Pharmaceuticals against its 20 peers (data as of 18 Nov 2026)
MeasureFENCPeer medianRank in peer set
1-month return+27.4%-10.8%highest of 21
6-month return+36.7%-15.8%3rd highest of 19
Distance from 52-week high-3.8%-44.1%highest of 21
Revenue growth (TTM)+71.1%-4.3%highest of 15
Operating margin4.9%-17.2%4th highest of 15
Forward P/E16.9×21.5×2nd cheapest of 6
Growth the price implies (Req g, 7 yrs)58.8%7.7%most demanding of 4
Growth delivered (Del g)+204.7%+7.0%highest of 4
Hurdle (Req g minus delivered)-145.9 pp+0.4 ppleast demanding of 4
Net debt / EBITDA-14.6×n/a—

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Fennec Pharmaceuticals FENCUnited States$471M+37%+71%5%16.9×58.8%+204.7%
TenNor Therapeutics Suzhou 6872.HKHong Kong$470Mn/an/an/an/an/an/a
Kamada KMDAUnited States$465M+3%+5%15%17.9×5.0%+6.5%
DiaMedica Therapeutics DMACUnited States$463M+50%n/an/an/an/an/a
Neurogene NGNEUnited States$479M-14%-100%n/an/an/an/a
HanchorBio 7827.TWTaiwan$462Mn/an/a-4,673%2.3×n/an/a
Monopar Therapeutics MNPRUnited States$479M+9%n/an/an/an/an/a
TaiMed Biologics 4147.TWOTaiwan$480M+19%+7%-31%n/an/an/a
Crescent Biopharma CBIOUnited States$482M-34%n/a-1,217%n/an/an/a
Shattuck Labs STTKUnited States$455M-28%-100%n/an/an/an/a
Komipharm International 041960.KSSouth Korea$454M-2%-6%-1%n/an/an/a
CHO Pharma 6586.TWOTaiwan$488M+24%-47%-17,694%n/an/an/a
Liaoning Dingjide Petrochemical 603255.SSChina$490M-24%+70%5%37.5×n/an/a
Qurient 115180.KSSouth Korea$452M-56%-14%-512%n/an/an/a
Sinotherapeutics 688247.SSChina$494M-19%-17%0%n/a29.4%+7.0%
EirGenix 6589.TWTaiwan$444M+15%+58%-51%n/an/an/a
Arvinas ARVNUnited States$443M-26%-12%-10%n/an/an/a
Beijing Scitop Bio-Tech 300858.SZChina$501M-28%+4%8%21.5×n/an/a
IRulya Therapeutics IRLAUnited States$440M+88%n/an/an/an/an/a
Berry Genomics 000710.SZChina$439M-17%-2%-24%n/an/an/a
Qingdao Vland Biotech 603739.SSChina$437M-24%+5%7%33.9×7.7%+7.3%

Questions

Which companies are Fennec Pharmaceuticals's closest peers?
The cockpit's peer set: TenNor Therapeutics Suzhou (6872.HK), Kamada (KMDA), DiaMedica Therapeutics (DMAC), Neurogene (NGNE), HanchorBio (7827.TW), Monopar Therapeutics (MNPR), TaiMed Biologics (4147.TWO), Crescent Biopharma (CBIO).
Is Fennec Pharmaceuticals expensive compared with its peers?
On forward p/e it trades at 16.9× against a peer median of 21.5×, 2nd cheapest of 6 in its peer set. For today's price to make sense, revenue must grow about 59% a year for seven years (Req g). Recent delivered growth is +205%, so the hurdle is -146 pp: the price already allows for a slowdown.
How has Fennec Pharmaceuticals stock performed?
Over six months to 18 Nov 2026 the shares returned +36.7% against -15.8% for the median peer; over one year +52.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.